Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)

Next Previous
Trial Profile

A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary) ; Sozinibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Opthea

    • Most Recent Events

    • 19 Mar 2024 According to an Opthea media release, will host a virtual key opinion leader (KOL) event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts including the Phase 2b data demonstrating superiority in combination with standard-of-care therapy.
    • 01 Jun 2023 Results assessing safety and efficacy of OPT-302 in combination with ranibizumab published in the Ophthalmology.
    • 13 Feb 2023 According to Opthea media release, the results from this study has been published in the journal of the American Academy of Ophthalmology. The published research article in ophthalmology titled is available as "A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration" can be accessed under "Articles in Press" at: https://www.aaojournal.org/article/S0161-6420(23)00066-0/fulltext."
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top